Current application of chimeric antigen receptor T cell immunotherapy and related laboratory examinations / 中华检验医学杂志
Chinese Journal of Laboratory Medicine
;
(12): 871-874, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-958593
ABSTRACT
Chimeric antigen receptor (CAR)-T cell immunotherapy is a revolutionary advancement in cancer treatment, and is highly effective in treatment of B cell leukemia, lymphoma, and multiple myeloma. However, it has some deficiencies such as antigen escape, antigen heterogeneity, toxic and side effects, which also pose challenges for therapy of other hematological malignancies and solid tumors. Comprehensive and continuous laboratory monitoring before and after CAR-T cell immunotherapy plays an important role in early warning of toxic and side effects, as well as theraputic evaluation. In the future, new breakthroughs for tumor therapy. Should be focused on improving CAR-T cells design, enhancing their anti-tumor activity, and optimizing therapeutic regimen.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Laboratory Medicine
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS